Over-expression of PIM1 and PIM2 kinases has been reported in hematologic malignancies also in solid tumors such as diffuse large B cell lymphomas (DLBCL) and prostate cancer [3], thus, these findings make it an attractive target for cancer therapy [1]. Here, PIM2 is linked to diffuse large B-cell lymphoma.